Abstract:Cancer stem cells (CSCs) are a small population of undifferentiated cancer cells within tumors, which contribute to tumorigenicity and relapse. In the current study, CD133 (also termed prominin-1), a CSC marker, was investigated to determine its involvement in predicting carcinogenesis and prognosis in patients with non-small cell lung carcinoma (NSCLC). CD133-positive lung cancer cells were isolated to analyze self-renewal, differentiation and tumorigenic abilities in vitro and in vivo. Quantitative polymerase chain reaction was used to detect the expression of CD133 and three other CSC-associated markers, octamer-binding transcription factor 4 (OCT4A), Nanog homeobox (NANOG) and multidrug resistance protein 1 (MDR1), in primary NSCLC and adjacent non-cancer tissues. A series of statistical methods were used to analyze the correlation between mRNA expression levels, clinicopathological features and patient survival. The results showed that CD133-positive NSCLC cells demonstrated clonogenic, tumorigenic and drug-resistance properties compared with their CD133-negative counterparts or parental cells. In addition, compared with the adjacent normal lung tissue, the levels of CSC-associated biomarkers CD133, OCT4A, NANOG and MDR1 were significantly increased in NSCLC tissue. Elevated expression of CD133 was associated with stage, tumor size and differentiation of NSCLC; however, the cox hazard regression analysis showed no significant association between CD133 expression and overall patient survival. The present study supports the hypothesis that the stem cell population can be enriched in cells expressing the CD133 cell surface marker and that highly expressed CD133 is involved in the occurrence of NSCLC. However, CD133 may not be considered as an independent factor in predicting the prognosis of patients with NSCLC. Further studies are required to investigate the association between CD133 expression and overall patient survival.

Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cells.

Expression of Dedifferentiation Markers and Multilineage Markers in U251 Glioblastoma Cells with Silenced EGFR and FGFR Genes.

Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells

Impact of CD133 gene overexpression on biological characteristics of human glioma U251 cells

Quantitative Analyses of CD133 Expression Facilitate Researches on Tumor Stem Cells.

Detection of CD133 expression in U87 glioblastoma cells using a novel anti-CD133 monoclonal antibody.

G Protein-Coupled Receptor 87 (Gpr87) Promotes The Growth And Metastasis Of Cd133(+) Cancer Stem-Like Cells In Hepatocellular Carcinoma

Activation of Akt and MAPK Pathways Enhances the Tumorigenicity of CD133+ Primary Colon Cancer Cells

CD133 in brain tumor: the prognostic factor

Cd133 Negative Glioma Cells Form Tumors in Nude Rats and Give Rise to Cd133 Positive Cells

CD133-negative Glioma Cells Form Tumours, While the Onset of CD133 Expression Coincides with Angiogenesis and Shortened Survival

CD133 Stimulates Cell Proliferation via the Upregulation of Amphiregulin in Melanoma

Prognostic Significance of Stem Cell Marker Cd133 Determined by Promoter Methylation but Not by Immunohistochemical Expression in Malignant Gliomas

Expression of CD133 Gene in Gliomas and Its Correlation with Malignancy of the Tumor

Resistance of Glioma Cells to Nutrient-Deprived Microenvironment Can Be Enhanced by CD133-mediated Autophagy.

Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis

Data from Glioma Cell Populations Grouped by Different Cell Type Markers Drive Brain Tumor Growth

CDK2 induces ALDH1A3-dependent proneural-mesenchymal transformation and promotes cell proliferation in glioma stem cells

The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.

Expression of CD133 in endometrial cancer cells and its implications

Expression of bone morphogenetic protein receptor in the early differentiated glioblastoma tumor initiating cells